Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
How Kenya has become a clinical logistics hub for sub-Saharan Africa
With Africa possessing immense potential for clinical trials that is largely untapped, Kenya has emerged as a strategic hub for clinical logistics.
Read Full Article
Pharma Tech
Chinaās burgeoning novel medicines success presents opportunity for EuropeĀ Ā
Experts at BIO-Europe 2026 say that Europe should seize the opportunity to rethink its legacy approaches to keep up as China races ahead.
Read Full Article
Pharma Tech
Delix Therapeutics raises $100m for zalsupindoleĀ development
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.
Read Full Article
Pharma Tech
Charles River agrees $470m deal for Frontage assets
CRL has signed definitive agreements to acquire Frontageās bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.
Read Full Article
Pharma Tech
Network Bio partners with Duke University on AI disease models
Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
Pharma Tech
Nov 10, 2026, 11:09 AM
How Kenya has become a clinical logistics hub for sub-Saharan Africa
With Africa possessing immense potential for clinical trials that is largely untapped, Kenya has emerged as a strategic hub for clinical logistics.
PharmaShots
Nov 10, 2026, 11:03 AM
Amgen Presents New Data of Repatha (Evolocumab) Including VESALIUS-CV Analysis in CKD at AHA 2026
Shots: Amgen has presented new data of Repatha (evolocumab) at AHA 2026, incl. a pre-specified P-III VESALIUS-CV analysis in high-risk patients with CKD & no prior heart attack or stroke In CKD patients, Repatha reduced 3-P MACE by 39%, 4-P MACE by 23% & all-cause death by 29% over a median follow-up of 4.6yrs; anā¦ The post Amgen Presents New Data of Repatha (Evolocumab) Including VESALIUS-CV Analysis in CKD at AHA 2026 appeared first on PharmaShots.
PharmaShots
Nov 10, 2026, 11:02 AM
Ribo Submits CTA in the EU for P-I Trial of Dual-Targeting siRNA SR122 to Treat Dyslipidemia
Shots: Suzhou Ribo Life Science & its subsidiary Ribocure Pharmaceuticals have submitted a P-I CTA in the EU for SR122, a dual GalNAc-conjugated siRNA, to treat dyslipidemia, incl. severe hypertriglyceridemia (sHTG) & mixed dyslipidemia The randomized, placebo-controlled P-I trial will evaluate the safety, tolerability, PK & PD of SC SR122 in healthy participants, providing theā¦ The post Ribo Submits CTA in the EU for P-I Trial of Dual-Targeting siRNA SR122 to Treat Dyslipidemia appeared first on PharmaShots.
PharmaShots
Nov 10, 2026, 11:01 AM
Cepheid Receives CE Mark Under IVDR for Xpert Respiratory Panel to Detect 13 Respiratory Pathogens
Shots: Cepheid, a Danaher company, has received the CE mark under the IVDR for its Xpert Respiratory Panel, a multiplex PCR test to aid in the diagnosis of suspected respiratory tract infection from a single nasopharyngeal swab sample The test detects 13 viral & bacterial pathogens, incl. SARS-CoV-2, influenza A & B, RSV, human metapneumovirus,ā¦ The post Cepheid Receives CE Mark Under IVDR for Xpert Respiratory Panel to Detect 13 Respiratory Pathogens appeared first on PharmaShots.
PharmaShots
Nov 10, 2026, 11:01 AM
Valneva Reports Five-Year Antibody Persistence Data of Single-Dose Chikungunya Vaccine Ixchiq
Shots: Valneva has reported 5yr antibody persistence data from the VLA1553-303 trial of its single-dose chikungunya vaccine, Ixchiq, supported by CEPI & the EUās Horizon Europe program Among 221 evaluable healthy adults at Yr5, 94% maintained neutralizing antibody titers above the seroresponse threshold, with comparable GMTs & seroresponse rates in adults aged ā„65yrs & 18-64yrs,ā¦ The post Valneva Reports Five-Year Antibody Persistence Data of Single-Dose Chikungunya Vaccine Ixchiq appeared first on PharmaShots.
PharmaShots
Nov 10, 2026, 10:57 AM
Alnylam Reports Five-Year P-III (HELIOS-B) Data of Amvuttra (Vutrisiran) for ATTR-CM at AHA 2026
Shots: Alnylam has presented 5yr data from the P-III HELIOS-B study, incl. the 2yr OLE, evaluating Amvuttra (vutrisiran) vs delayed start (placebo switched to vutrisiran in OLE) in ATTR-CM patients at AHA 2026 Continuous treatment reduced the risk of all-cause mortality & recurrent CV events by 48% (monotherapy; n=395) & 41% (overall; n=654) & recurrentā¦ The post Alnylam Reports Five-Year P-III (HELIOS-B) Data of Amvuttra (Vutrisiran) for ATTR-CM at AHA 2026 appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 10, 2026, 9:45 PM
Sonoma Pharmaceuticals Q2 Results: Loss narrows 97% YoY, sales up 28% - scanx.trade
Sonoma Pharmaceuticals Q2 Results: Loss narrows 97% YoY, sales up 28%Ā Ā scanx.trade
Google News
Nov 10, 2026, 9:06 PM
Here's Why We Think Cell Biotech (KOSDAQ:049960) Might Deserve Your Attention Today - Simply Wall St
Here's Why We Think Cell Biotech (KOSDAQ:049960) Might Deserve Your Attention TodayĀ Ā Simply Wall St
Google News
Nov 10, 2026, 9:01 PM
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE - Quantisnow
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATEĀ Ā Quantisnow
Google News
Nov 10, 2026, 9:01 PM
Primary Progressive Multiple Sclerosis Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - StreetInsider
Primary Progressive Multiple Sclerosis Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightĀ Ā StreetInsider
Google News
Nov 10, 2026, 9:00 PM
Chronic Myeloid Leukemia Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - StreetInsider
Chronic Myeloid Leukemia Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightĀ Ā StreetInsider
Google News
Nov 10, 2026, 8:47 PM
Proximal Ventures raises debut fund to back startups bringing AI to drug development - TechCrunch
Proximal Ventures raises debut fund to back startups bringing AI to drug developmentĀ Ā TechCrunch
Google News
Nov 10, 2026, 7:39 PM
Thin physiques are trending again, so drug companies like Eli Lilly are capitalizing on it - The Central Trend
Thin physiques are trending again, so drug companies like Eli Lilly are capitalizing on itĀ Ā The Central Trend
Google News
Nov 10, 2026, 7:37 PM
Business Watch: 3M settles PFAS cases for $7.35 billion, and more - Chemical & Engineering News
Business Watch: 3M settles PFAS cases for $7.35 billion, and moreĀ Ā Chemical & Engineering News
Google News
Nov 10, 2026, 7:27 PM
Pharma firmsā focus on weight-loss drugs could put insulin supply at risk, experts warn - The Guardian
Pharma firmsā focus on weight-loss drugs could put insulin supply at risk, experts warnĀ Ā The Guardian
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer